Levophed a vasopressor?

See the DrugPatentWatch profile for Levophed

What is Levophed?
Levophed is the brand name for the intravenous vasopressor norepinephrine. It raises blood pressure by constricting arterioles and venules, making it a first‑line drug for treating septic shock and other forms of hypotension. [1]

When is Levophed typically started?
Clinicians begin Levophed when a patient’s blood pressure is insufficient to maintain adequate organ perfusion despite fluid resuscitation. It is usually started in an intensive care setting and titrated to keep mean arterial pressure above 65 mm Hg. [2]

How is the dose adjusted?
Levophed is delivered via a continuous infusion that starts at 0.01 µg/kg/min and can be increased by 0.01 µg/kg/min steps up to 0.1 µg/kg/min, depending on the patient’s response. The goal is to keep systolic pressure in a target range while avoiding excessive vasoconstriction. [2]

What side effects do patients notice?
Common adverse reactions include arrhythmias, tissue ischemia at the infusion site, and, rarely, paradoxical hypotension if the infusion is stopped abruptly. Because norepinephrine is a potent catecholamine, monitoring for heart rate changes is essential. [2]

How does Levophed compare to other vasopressors?
Compared with dopamine or phenylephrine, norepinephrine has a stronger α‑adrenergic effect and a lower propensity to cause tachyarrhythmias. It is preferred for septic shock but may be combined with vasopressin if the target blood pressure cannot be reached alone. [2]

Can a biosimilar or generic replace Levophed?
Norepinephrine itself is a generic compound. However, the Levophed brand name is protected by a patent that expired in the early 2020s, after which generic formulations entered the market. [1] Generics provide the same pharmacologic effect at a lower cost, though clinicians often prefer the established brand for consistency in critical care settings.

Who manufactures Levophed and what’s the price trend?
The original manufacturer held exclusive rights until the patent expired, after which multiple suppliers produce generic norepinephrine. Pricing varies by institution and region but generics typically cut costs by 20–30 % compared with brand‑name products. [1]

When will the next patent expire?
The most recent patents covering the formulation and delivery system for Levophed expired in 2023. No new patents are expected to extend exclusivity for several years, allowing continued generic competition. [1]

What regulatory approvals does Levophed have?
Levophed is approved by the FDA as a vasopressor for the treatment of severe hypotension. It is classified as a Class II drug, requiring routine pre‑market review but no clinical trial evidence beyond safety and effectiveness studies. [2]

Are there ongoing studies or new indications?
Research is examining levophed’s role in traumatic shock and cardiac arrest resuscitation. Early data suggest benefits when used early in the resuscitation protocol, but larger trials are needed to confirm these findings. [2]

How do patients feel about using Levophed?
Patient concerns center on the invasiveness of IV lines and the risk of arrhythmias. Clear communication about the necessity of rapid blood pressure control and the short‑term nature of therapy often alleviates anxiety. [2]

Sources
1. DrugPatentWatch.com – patent status and generic availability of Levophed. https://www.drugpatentwatch.com
2. U.S. Food & Drug Administration – prescribing information for Levophed (norepinephrine). https://www.fda.gov